SCHEMBL17078990

SCHEMBL17078990

C[C@@H]1CN(Cc2cccc(CN3CCCC3)c2)C[C@H](C)N1Cc1ccc(C=CC(=O)NO)cc1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 18/20 0.56
▸ HDAC6 Q9UBN7 11/20 0.56
▸ HDAC8 Q9BY41 11/20 0.55
▸ HDAC3 O15379 10/20 0.55
▸ HDAC4 P56524 10/20 0.55
▸ HDAC7 Q8WUI4 10/20 0.55
▸ HDAC2 Q92769 10/20 0.55
▸ HDAC10 Q969S8 10/20 0.55
▸ HDAC11 Q96DB2 10/20 0.55
▸ HDAC9 Q9UKV0 10/20 0.55
▸ HDAC5 Q9UQL6 10/20 0.55
▸ KCNH2 Q12809 6/20 0.49
▸ CHRM1 P11229 1/20 0.49
▸ HTR2A P28223 1/20 0.49
▸ MCHR1 Q99705 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17078988 1.00 HDAC1 (0.56) HDAC1HDAC6HDAC8HDAC3HDAC4
SCHEMBL20432773 0.91 RAB9A (0.56) HDAC1HDAC6HDAC8HDAC3HDAC4
SCHEMBL17079053 0.91 RAB9A (0.56) HDAC1HDAC6HDAC8HDAC3HDAC4
SCHEMBL17079054 0.91 RAB9A (0.56) HDAC1HDAC6HDAC8HDAC3HDAC4
SCHEMBL20433060 0.91 RAB9A (0.56) HDAC1HDAC6HDAC8HDAC3HDAC4
SCHEMBL17079076 0.90 HDAC1 (0.53) HDAC1HDAC6HDAC8HDAC3HDAC4
SCHEMBL17079077 0.90 HDAC1 (0.53) HDAC1HDAC6HDAC8HDAC3HDAC4
SCHEMBL20966258 0.90 HDAC1 (0.53) HDAC1HDAC6HDAC8HDAC3HDAC4
SCHEMBL20421076 0.90 HDAC1 (0.53) HDAC1HDAC6HDAC8HDAC3HDAC4
SCHEMBL17078613 0.89 HDAC1 (0.57) HDAC1HDAC6HDAC8HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3116859-B1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2018-08-01 — — EP claimed
US-10287255-B2 Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2019-05-14 — — US disclosed
EP-3116859-B1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2018-08-01 — — EP disclosed
US-20170096405-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2017-04-06 — — US disclosed
EP-3116859-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2017-01-18 — — EP disclosed
WO-2015137750-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2015-09-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287255-B2 Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same HDAC6, HDAC1, HDAC11 HDAC1 2/4885HDAC6 1/4885HDAC8 11/4885
US-20170096405-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME HDAC6, HDAC1, HDAC5 HDAC1 2/4885HDAC6 1/4885HDAC8 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback